



US 20210101994A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2021/0101994 A1

Madiyalakan et al.

(43) Pub. Date: Apr. 8, 2021

(54) MUC16 MONOCLONAL ANTIBODY AND USES THEREOF

(71) Applicant: QUEST PHARMATECH INC., Edmonton, Alberta (CA)

(72) Inventors: Ragupathy Madiyalakan, Edmonton, Alberta (CA); Michael Hollingsworth, Omaha, NE (US); Prakash Radhakrishnan, Omaha, NE (US)

(21) Appl. No.: 17/048,119

(22) PCT Filed: Apr. 30, 2019

(86) PCT No.: PCT/CA2019/050565

§ 371 (c)(1),

(2) Date: Oct. 16, 2020

**Related U.S. Application Data**

(60) Provisional application No. 62/669,058, filed on May 9, 2018.

**Publication Classification**

(51) Int. Cl.

C07K 16/30 (2006.01)

(52) U.S. Cl.

CPC .... C07K 16/3092 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); A61K 45/06 (2013.01); C07K 2317/622 (2013.01); C07K 2317/24 (2013.01); C07K 2317/569 (2013.01)

(57)

**ABSTRACT**

The present document describes an antibody or an antigen-binding fragment that bind to O-glycan mucin-type glycoprotein MUC16 comprising three variable heavy domain complementarity determining regions (CDR)(CDR H1, H2 and H3), and three variable light domain CDR (CDR L1, L2 and L3). The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of inhibiting tumor growth of a tumor expressing O-glycan mucin-type glycoprotein MUC16.

**Specification includes a Sequence Listing.**